Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Financial Officer | March 19, 2024 | March 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date March 19, 2024 · Filed March 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 246,534 |
Reported balance
After 2024-03-19 transaction · row 1
1 source rowRow 1 · 2024-03-19 · Exercise / conversion · Acquired 20,041 · Balance 246,534 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2025-05-19 | Direct | 0 |
Reported balance
After 2024-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-19 · Exercise / conversion · Disposed 20,041 · Balance 0 F1: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2024 Filed Mar 21, 2024 17:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,041 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-002907 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,041 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 17:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 20,041 | $3.76 | $75,354.16 |
DisclosureSEC source: 0001562180-24-002907 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 76,313 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001562180-24-000246 · primarydocument.xml · derivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,313 Underlying: Common Stock · 76,313 shares Expires 2034-01-02 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 16,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000246 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,493 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 4,534 | $17.95 | $81,385.30 |
DisclosureSEC source: 0001562180-24-000246 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,467 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-23-004722 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2024-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise have vested monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 35,000 | $0.85 | $29,750.00 |
DisclosureSEC source: 0001562180-23-004722 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 66,233 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001562180-23-000224 · primarydocument.xml · derivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,233 Underlying: Common Stock · 66,233 shares Expires 2033-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 46,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000224 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,001 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,333 | $22.68 | $30,232.44 |
DisclosureSEC source: 0001562180-23-000224 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,827 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022. Read SEC document |
| August 30, 2022 Filed Aug 31, 2022 18:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,400 | $30.24 | $72,572.64 |
DisclosureSEC source: 0001562180-22-006398 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,160 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.04 to $30.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 16:04 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 17,280 | $35.19 | $608,034.82 |
DisclosureSEC source: 0001562180-22-005938 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,560 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 16:04 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 400 | $35.00 | $14,000.00 |
DisclosureSEC source: 0001562180-22-005938 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,840 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,400 | $31.26 | $75,012.00 |
DisclosureSEC source: 0001562180-22-005876 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,240 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.85 to $31.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 16:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 468 | $30.00 | $14,040.00 |
DisclosureSEC source: 0001562180-22-005681 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,640 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 16:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,332 | $30.01 | $129,988.16 |
DisclosureSEC source: 0001562180-22-005681 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,108 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.0000 to $30.0065. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 16:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 29,900 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-22-000597 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 29,900 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: (Continued from footnote 1) Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise have vested monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 16:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 29,900 | $0.85 | $25,415.00 |
DisclosureSEC source: 0001562180-22-000597 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:07 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $34.31 | $0.00 |
DisclosureSEC source: 0001562180-22-000170 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2032-01-03 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:07 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 8,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000170 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,540 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 16:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-21-005088 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common Stock · 10,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: (Continued from footnote 1) Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise have vested monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 16:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $0.85 | $8,500.00 |
DisclosureSEC source: 0001562180-21-005088 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 16:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 252 | $50.04 | $12,610.08 |
DisclosureSEC source: 0001562180-21-000379 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,640 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 18:53 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 11,093 | $50.03 | $554,982.79 |
DisclosureSEC source: 0001562180-21-000344 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 18:53 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,200 | $50.01 | $210,042.00 |
DisclosureSEC source: 0001562180-21-000344 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,985 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 16:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 573 | $48.15 | $27,589.95 |
DisclosureSEC source: 0001562180-21-000283 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,185 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $47.98 to $48.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 16:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,208 | $47.49 | $104,857.92 |
DisclosureSEC source: 0001562180-21-000283 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $46.92 to $47.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 16:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,460 | $46.45 | $114,267.00 |
DisclosureSEC source: 0001562180-21-000283 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,966 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.92 to $46.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 16:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,998 | $50.00 | $549,900.00 |
DisclosureSEC source: 0001562180-21-000283 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,426 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.095. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 08:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 56,200 | $0.00 Strike: $44.97 | $0.00 |
DisclosureSEC source: 0001562180-21-000144 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,200 Underlying: Common Stock · 56,200 shares Expires 2031-01-04 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 08:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 12,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000144 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,424 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 16:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,376 | $50.00 | $168,800.00 |
DisclosureSEC source: 0001562180-20-007470 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,024 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 21,124 | $50.01 | $1,056,411.24 |
DisclosureSEC source: 0001562180-20-007470 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,400 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 14,916 | $40.17 | $599,175.72 |
DisclosureSEC source: 0001562180-20-007250 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,524 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 22,584 | $40.06 | $904,715.04 |
DisclosureSEC source: 0001562180-20-007250 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,440 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,259 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-005162 · primarydocument.xml · derivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,115 Underlying: Common Stock · 3,259 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 14,950 | $40.10 | $599,495.00 |
DisclosureSEC source: 0001562180-20-005162 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,024 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,259 | $13.09 | $42,660.31 |
DisclosureSEC source: 0001562180-20-005162 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-003531 · primarydocument.xml · derivative · entry 6 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,374 Underlying: Common Stock · 500 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 500 | $40.00 | $20,000.00 |
DisclosureSEC source: 0001562180-20-003531 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,715 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 500 | $13.09 | $6,545.00 |
DisclosureSEC source: 0001562180-20-003531 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 08, 2020 Filed May 12, 2020 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-003531 · primarydocument.xml · derivative · entry 5 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,874 Underlying: Common Stock · 2,500 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| May 08, 2020 Filed May 12, 2020 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 7,000 | $40.18 | $281,260.00 |
DisclosureSEC source: 0001562180-20-003531 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,715 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 08, 2020 Filed May 12, 2020 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,500 | $13.09 | $32,725.00 |
DisclosureSEC source: 0001562180-20-003531 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-003177 · primarydocument.xml · derivative · entry 6 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,374 Underlying: Common Stock · 3,000 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 12,000 | $40.11 | $481,320.00 |
DisclosureSEC source: 0001562180-20-003177 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,000 | $13.09 | $39,270.00 |
DisclosureSEC source: 0001562180-20-003177 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-003177 · primarydocument.xml · derivative · entry 5 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,374 Underlying: Common Stock · 3,000 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,000 | $40.00 | $120,000.00 |
DisclosureSEC source: 0001562180-20-003177 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,000 | $13.09 | $39,270.00 |
DisclosureSEC source: 0001562180-20-003177 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.